Trial Profile
A Phase 1b Dose-escalation Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX2853 in Subjects With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 28 Jul 2022
Price :
$35
*
At a glance
- Drugs PLX-2853 (Primary)
- Indications Colorectal cancer; Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours; Uveal melanoma
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors Plexxikon
- 04 Feb 2022 Status changed from recruiting to completed.
- 08 Jun 2021 Results (n=44; Data cut off date- 2 February 2021) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 24 Mar 2021 Planned End Date changed from 1 Oct 2021 to 1 Jun 2022.